Cargando…
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment optio...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406805/ https://www.ncbi.nlm.nih.gov/pubmed/30736352 http://dx.doi.org/10.3390/jcm8020200 |
_version_ | 1783401408342523904 |
---|---|
author | Hofmann, Susanne Schubert, Maria-Luisa Wang, Lei He, Bailin Neuber, Brigitte Dreger, Peter Müller-Tidow, Carsten Schmitt, Michael |
author_facet | Hofmann, Susanne Schubert, Maria-Luisa Wang, Lei He, Bailin Neuber, Brigitte Dreger, Peter Müller-Tidow, Carsten Schmitt, Michael |
author_sort | Hofmann, Susanne |
collection | PubMed |
description | Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients. |
format | Online Article Text |
id | pubmed-6406805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64068052019-03-22 Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) Hofmann, Susanne Schubert, Maria-Luisa Wang, Lei He, Bailin Neuber, Brigitte Dreger, Peter Müller-Tidow, Carsten Schmitt, Michael J Clin Med Review Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients. MDPI 2019-02-06 /pmc/articles/PMC6406805/ /pubmed/30736352 http://dx.doi.org/10.3390/jcm8020200 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hofmann, Susanne Schubert, Maria-Luisa Wang, Lei He, Bailin Neuber, Brigitte Dreger, Peter Müller-Tidow, Carsten Schmitt, Michael Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
title | Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
title_full | Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
title_fullStr | Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
title_full_unstemmed | Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
title_short | Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
title_sort | chimeric antigen receptor (car) t cell therapy in acute myeloid leukemia (aml) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406805/ https://www.ncbi.nlm.nih.gov/pubmed/30736352 http://dx.doi.org/10.3390/jcm8020200 |
work_keys_str_mv | AT hofmannsusanne chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml AT schubertmarialuisa chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml AT wanglei chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml AT hebailin chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml AT neuberbrigitte chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml AT dregerpeter chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml AT mullertidowcarsten chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml AT schmittmichael chimericantigenreceptorcartcelltherapyinacutemyeloidleukemiaaml |